Nuvalent climbs as investors price in neladalkib FDA NDA submission momentum
Nuvalent shares are rising as investors react to the company’s April 7, 2026 submission of an FDA New Drug Application for neladalkib in TKI-pretreated advanced ALK-positive non-small cell lung cancer. The NDA milestone adds a second major regulatory catalyst alongside zidesamtinib, which already has an FDA action date of September 18, 2026.
1. What’s moving the stock today
Nuvalent (NUVL) is up about 3% as traders continue to position around a fresh regulatory milestone: the company filed a New Drug Application with the FDA on April 7, 2026 for neladalkib in tyrosine kinase inhibitor (TKI) pretreated advanced ALK-positive non-small cell lung cancer. The filing is a key de-risking event for a clinical-stage biotech because it marks the transition from development into an FDA review process for a potential commercial product. (investors.nuvalent.com)
2. Why this catalyst matters
The neladalkib NDA puts Nuvalent on track to potentially pursue a second approval pathway, complementing its lead ROS1 program. Investors are also focused on the company’s other near-term FDA catalyst: zidesamtinib already has a target FDA action date of September 18, 2026, keeping 2026 positioned as a high-catalyst year for the pipeline. (royaltypharma.com)
3. What to watch next
Near-term trading will likely hinge on any updates on FDA acceptance and timing for neladalkib’s application, plus additional clinical and scientific disclosures as the oncology conference calendar progresses. With multiple late-stage programs approaching regulatory decision points, incremental updates on review status, labeling expectations, and launch-readiness can quickly change investor expectations for timing and market opportunity. (investors.nuvalent.com)